Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug

Sarepta Therapeutics (SRPT) announced Tuesday that the Food and Drug Administration agreed to an accelerated approval process for its treatment for certain patients with Duchenne muscular dystrophy. The news boosted SRPT stock.